150 related articles for article (PubMed ID: 24005614)
1. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Valentin T; Fournier C; Penel N; Bompas E; Chaigneau L; Isambert N; Chevreau C
Invest New Drugs; 2013 Dec; 31(6):1626-7. PubMed ID: 24005614
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Bompas E; Le Cesne A; Tresch-Bruneel E; Lebellec L; Laurence V; Collard O; Saada-Bouzid E; Isambert N; Blay JY; Amela EY; Salas S; Chevreau C; Bertucci F; Italiano A; Clisant S; Penel N
Ann Oncol; 2015 Oct; 26(10):2168-73. PubMed ID: 26202596
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
[TBL] [Abstract][Full Text] [Related]
7. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
9. Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L; Bertucci F; Tresch-Bruneel E; Bompas E; Toiron Y; Camoin L; Mir O; Laurence V; Clisant S; Decoupigny E; Blay JY; Goncalves A; Penel N
Oncotarget; 2016 Nov; 7(45):73984-73994. PubMed ID: 27659533
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Cruz J; Penel N; Le Cesne A; Hindi N; Luna P; Moura DS; Bernabeu D; de Alava E; Lopez-Guerrero JA; Dopazo J; Peña-Chilet M; Gutierrez A; Collini P; Karanian M; Redondo A; Lopez-Pousa A; Grignani G; Diaz-Martin J; Marcilla D; Fernandez-Serra A; Gonzalez-Aguilera C; Casali PG; Blay JY; Stacchiotti S
Lancet Oncol; 2020 Mar; 21(3):456-466. PubMed ID: 32066540
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
[TBL] [Abstract][Full Text] [Related]
17. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
Bugalho MJ
J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
[TBL] [Abstract][Full Text] [Related]
18. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865
[TBL] [Abstract][Full Text] [Related]
19. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
[No Abstract] [Full Text] [Related]
20. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Reed DR; Mascarenhas L; Manning K; Hale GA; Goldberg J; Gill J; Sandler E; Isakoff MS; Smith T; Caracciolo J; Lush RM; Juan TH; Lee JK; Neuger AM; Sullivan DM
Cancer Med; 2016 Feb; 5(2):294-303. PubMed ID: 26714427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
